A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM).

Amaria, Rodabe N.; Haymaker, Cara L.; Bernatchez, Chantale; Forget, Marie-Andrée; Patel, Vruti; Hwu, Wen‐Jen; Davies, Michael A.; Patel, Sapna; Diab, Adi; Glitza, Isabella C.; Tawbi, Hussein Abdul-Hassan; Woodman, Scott E.; Wargo, Jennifer A.; Ross, Merrick I.; Lee, Jeffrey Edwin; Gershenwald, Jeffrey E.; Cormier, Janice N.; Royal, Richard E.; Lucci, Anthony; Hwu, Patrick

doi:10.1200/jco.2016.34.15_suppl.tps9594

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Redirecting of T cells against stromal cell-associated antigens in addition to classic tumor targeting could also improve local delivery. Such strategies are being investigated in solid tumors in the context of TIL-based ACT and CAR-T [ 68 , 69 ].…”

Section: Endogenous Actmentioning

confidence: 99%

Cellular Therapy in NSCLC: Between Myth and Reality

Imbimbo,

Wetterwald,

Friedlaender

et al. 2023

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review In this paper, we review the current state and modalities of adoptive cell therapies (ACT) in non-small cell lung carcinoma (NSCLC). We also discuss the challenges hampering the use of ACT and the approaches to overcome these barriers. Recent Findings Several trials are ongoing investigating the three main modalities of T cell-based ACT: tumor-infiltrating lymphocytes (TILs), genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells. The latter, in particular, has revolutionized the treatment of hematologic malignancies. However, the efficacy against solid tumor is still sparse. Major limitations include the following: severe toxicities, restricted infiltration and activation within the tumors, antigen escape and heterogeneity, and manufacturing issues. Summary ACT is a promising tool to improve the outcome of metastatic NSCLC, but significant translational and clinical research is needed to improve its application and expand the use in NSCLC.

show abstract

Section: Endogenous Actmentioning

confidence: 99%

Cellular Therapy in NSCLC: Between Myth and Reality

Imbimbo,

Wetterwald,

Friedlaender

et al. 2023

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…These findings have been validated in NOG mice bearing subcutaneous human melanoma xenografts, in which increased tumor homing and infiltration by CXCR2-engineered T cells was observed ( 75 ). In addition, a clinical trial with CXCR2-engineered in MM patients is currently ongoing ( 76 ). The methodology developed for this clinical trial has been described by Forget et al ( 77 ) and includes retroviral transduction and TIL expansion ( 83 ).…”

Section: Synthetic Tils With Enhanced Tumor Homing Abilitymentioning

confidence: 99%

Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential

et al. 2021

View full text Add to dashboard Cite

Immunotherapy has emerged as an effective and life-changing approach for several types of cancers, both liquid and solid tumors. In combination with traditional treatments such as radiotherapy and/or chemotherapy, immune checkpoints inhibitors have improved prognosis and overall survival of patients with advanced melanoma and many other cancers. Among adoptive cell therapies (ACT), while chimeric antigen receptor T cell therapies have demonstrated remarkable efficacy in some hematologic malignancies, such as B cell leukemias, their success in solid tumors remains scarce due to the characteristics of the tumor microenvironment. On the other hand, ACT using tumor-infiltrating lymphocytes (TILs) is arguably the most effective treatment for metastatic melanoma patients, but even if their isolation has been achieved in epithelial tumors, their success beyond melanoma remains limited. Here, we review several aspects impacting TIL- and gene-modified “synthetic” TIL-based therapies and discuss future challenges that must be addressed with these approaches.

show abstract

“… 37 For more than 30 years, this structure, with and also without the 155 aa cytoplasmic tail, has been used as a marker for successful gene transfer in research as well as clinical settings. 38 , 39 , 40 In 2002, the description of insertional mutagenesis in a murine transplantation model with a splice-active oncoretroviral vector, where the cytoplasmatically truncated NGFR (ΔNGFR) was expressed off the strong 5′ LTR, questioned the safety of using the ΔNGFR cDNA as transgene for human clinical applications. 41 However, Bonini et al.…”

Section: Introductionmentioning

confidence: 99%